Navigation Links
Amgen Statement on European Investor Visit
Date:11/14/2011

31, 2010, and in our periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. 

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
2. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
3. Amgen Announces Webcast of 2011 Third Quarter Financial Results
4. Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Conference
7. Amgen to Present at the Baird Healthcare Conference
8. Amgen to Present at the Stifel Nicolaus Healthcare Conference
9. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
10. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
11. Amgen Announces Webcast of 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Legal-Bay LLC, The Lawsuit ... Joseph Goodwin in the Southern District of ... transvaginal mesh cases against Ethicon for a single trial ... cases for the 26 women include claims from the ... made my Johnson & Johnson,s Ethicon subsidiary. The cases ...
(Date:7/1/2015)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... the Cantor Fitzgerald Healthcare Conference in New York ... Cox , executive vice president and chief operating officer, will ... financial update on Wednesday, July 8, 2015 at 9:30 a.m. ... audio webcast of the presentation may be accessed from the ...
(Date:7/1/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in European Clinical Chemistry and ... Landscape is a new five-country strategic analysis ...
Breaking Medicine Technology:Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 22015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2
... USANA Health Sciences, Inc. (NYSE: ... are common in the average American diet and that dietary ...  However, USANA scientists and advising physicians caution that many important ... Dietary Guidelines for Americans, 2010 and that the ...
... 10, 2011 For the biopharmaceutical industry, the ... and difficulty - of interacting with patients to ... created both opportunities and challenges for approaching and ... To help marketing teams in the biopharmaceutical ...
Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:7/2/2015)... ... , ... ActiveBunch.com recently launched as a social network created for people with ... lifestyle community, Active Bunch allows users to connect with like-minded fitness enthusiasts from around ... or group events. , The spokesperson for Active Bunch explained the idea behind ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... with care and precision. There is an art and science that goes into ... of successfully reshaping the facial features and lives of more than 2,500 satisfied ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from ... in Anniston for specialized disaster training. The team – composed of four clinicians ... California Hospital Association who attended the training, which is dedicated to preparing first ...
(Date:7/2/2015)... ... , ... After conducting a nationwide executive search led by healthcare ... Ariz., has hired Robert Trenschel, DO, as chief executive officer. A veteran physician executive ... his new duties at Yuma Regional Medical Center on July 13. , “Dr. Trenschel ...
(Date:7/2/2015)... ... 02, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it has made two key appointments at its ... Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid manufacturing ...
Breaking Medicine News(10 mins):Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... from product design and development through ... ... a,leading product design and development company, announced today that it has,received ... Services, Division of Food, Drug and Radiation Safety to,manufacture class I ...
... is the first Southern-style canned product ... by the American Heart Association, COLUMBUS, Ohio, Jan. ... lower sodium, low fat and meatless, were the first,product ... maintaining a savory,taste. Now, heart-healthy Sensibly Seasoned products also ...
... HARRISBURG, Pa., Jan. 9 Consumption of,sugary beverages can ... know that,some soft drinks contain as much as 11 ... also contain phosphoric and citric acids? Prolonged,exposure to these ... from the,tooth surface., According to Dr. Bruce Terry, ...
... Georgia Locations, ATLANTA, Jan. 9 Georgia Cancer Specialists ... -- will team,up with WSB-TV for the sixth annual "Totes ... GCS offices across Georgia on Friday, January 18,2008, from 10 ... or nearly new suitcases to foster children,in Georgia, many of ...
... say , , WEDNESDAY, Jan. 9 (HealthDay News) -- Researchers ... acid (RNA) molecules that seem to control whether or ... , These "microRNAs" essentially serve as brakes on the ... the disease to spread freely. When they are restored, ...
... WEDNESDAY, Jan. 9 (HealthDay News) -- Two new studies ... wisdom of treating with corticosteroids, intensive insulin therapy or ... , The first study compared the use of hydrocortisone ... found no improvement in survival rates. , The second ...
Cached Medicine News:Health News:Hiemstra Approved to Manufacture Medical Devices in New CER 2Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Keep a Watchful Eye on Sugary Beverage Consumption 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 2Health News:Tiny RNA Molecules Control Breast Cancer's Spread 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 4Health News:Standard Septic Shock Treatments Ineffective 2Health News:Standard Septic Shock Treatments Ineffective 3Health News:Standard Septic Shock Treatments Ineffective 4
... Opmi Vario/NC33 system microscope provides surgeons ... pathology. These microscopes are ideal for many ... compact. Ergonomically designed at every point of ... utilized in a surgical microscope allows intuitive ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
26 cm - 10 1/4, 140 mm - 5 1/2, bayonet-shaped, flexible, 90 angle, 4 mm...
Toothed pituitary rongeur....
Medicine Products: